Sarcoma News

CHICAGO — Aldoxorubicin monotherapy appeared well tolerated and may improve outcomes compared with standard treatments for relapsed/refractory soft tissue sarcoma, according to results of a phase 3 clinical trial presented at the ASCO Annual Meeting.

CHICAGO — Treatment modifications that extended survival for childhood cancer survivors during the past several decades also reduced incidence of serious chronic disease in these individuals later in life, according to study results presented at the ASCO Annual Meeting.

National Cancer Survivors Day, recognized annually on the first Sunday in June, provides free education and networking to hospitals, support groups and other cancer-related organizations to help improve the quality of life of cancer survivors.

South African men and women with HIV, as well as HIV–positive men who have sex with men on several continents, remained at increased risk for Kaposi sarcoma despite declining incidence of the disease, according to recently published findings.

Michael A. Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center, took over this spring as president of American Association for Cancer Research.

The FDA today granted accelerated approval to pembrolizumab for adults and children with unresectable or metastatic, microsatellite instability–high or mismatch repair–deficient solid tumors.

Younger age at the time of a second primary malignant neoplasm diagnosis appeared linked to worse survival outcomes among cancer survivors, according to a retrospective study published in JAMA Oncology.

Rare malignancies accounted for about one in five cancer diagnoses in the United States from 2009 to 2013, according to an American Cancer Society report published in CA: A Cancer Journal for Clinicians.

The FDA granted breakthrough therapy designation to entrectinib for the treatment of NTRK fusion–positive locally advanced or metastatic solid tumors, according to the drug’s manufacturer.

The FDA granted orphan drug designation to larotrectinib for the treatment of solid tumors with neurotrophic tyrosine receptor kinase–fusion proteins, according to the drug’s manufacturer.